TRINETRA › Sectors › Healthcare
Apollo Hospitals Enterprise Limited (APOLLOHOSP) — share price, P/E and fundamentals
Apollo Hospitals Enterprise Limited (NSE: APOLLOHOSP) closed at ₹8,448.00 on 30 Oct 2026, +6.9% over one year, against a 52-week range of ₹6,696.50 – ₹9,070.50.
In the quarter ended 30 Jun 2026 (consolidated, filed 12 Aug 2026) it reported revenue of ₹7,044 cr and net profit of ₹581 cr, a 8.2% net margin; revenue grew 20.6% and profit grew 38.0% year on year.
On four consecutive filed quarters its trailing P/E is 58.1; since 30 May 2025 its own P/E has ranged from 59.0 to 159.3 (median 110.2), and today's reading is higher than 5% of those 350 trading days.
From the balance sheet dated 31 Mar 2026: return on equity 24.5%, ROCE 23.1%, debt-to-equity 0.60, Piotroski F-score 8 of 9.
Against 65 Healthcare peers on NSE: Net margin higher than 19% of 63 sector peers; PBT margin higher than 18% of 63 sector peers; ROE higher than 86% of 63 sector peers.
Key figures
| Last close | ₹8,448.00 (30 Oct 2026) |
|---|---|
| Change 1 month / 6 months / 1 year | -5.0% / +9.3% / +6.9% |
| 52-week low – high | ₹6,696.50 – ₹9,070.50 |
| Market capitalisation | ₹1,21,482 cr |
| Trailing P/E | 58.1 |
| Price / book | 12.81 |
| EV / EBITDA | 30.2 |
| Earnings yield | 1.7% |
| TTM EPS | ₹145.31 |
| TTM net profit | ₹2,090 cr |
| Quarter revenue | ₹7,044 cr |
| Quarter net profit | ₹581 cr |
| Net margin | 8.2% |
| Revenue growth (YoY) | +20.6% |
| Profit growth (YoY) | +38.0% |
| Return on equity | 24.5% |
| ROCE | 23.1% |
| Debt / equity | 0.60 |
| Current ratio | 1.06 |
| Free cash flow | ₹894 cr |
| Piotroski F-score | 8 / 9 |
| Average daily turnover (50 days) | ₹312.0 cr |
Against Healthcare peers
| Metric | APOLLOHOSP | Peer median | Percentile |
|---|---|---|---|
| Net margin | 8.24 | 12.89 | 19 |
| PBT margin | 11.15 | 17.68 | 18 |
| ROE | 24.50 | 13.86 | 86 |
| ROCE | 23.05 | 16.59 | 73 |
| Debt / equity | 0.60 | 0.11 | 92 |
| Cash conversion | 1.43 | 1.25 | 65 |
| Trailing P/E | 58.14 | 43.07 | 68 |
| P/B | 12.81 | 5.88 | 82 |
Questions
What is the P/E ratio of Apollo Hospitals Enterprise Limited?
Apollo Hospitals Enterprise Limited's trailing P/E is 58.1, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Jun 2026. Since 30 May 2025 its P/E has ranged 59.0–159.3.
What were Apollo Hospitals Enterprise Limited's latest quarterly results?
For the quarter ended 30 Jun 2026, Apollo Hospitals Enterprise Limited reported revenue of ₹7,044 cr and net profit of ₹581 cr (consolidated), filed with the exchange on 12 Aug 2026.
What is Apollo Hospitals Enterprise Limited's ROE?
Return on equity is 24.5% based on the balance sheet dated 31 Mar 2026.
Does Apollo Hospitals Enterprise Limited have debt?
Debt-to-equity is 0.60 on the balance sheet dated 31 Mar 2026.
What is APOLLOHOSP's 52-week high and low?
Over the last 52 weeks to 30 Oct 2026, APOLLOHOSP traded between ₹6,696.50 and ₹9,070.50.
Other Healthcare stocks
- Sun Pharmaceutical Industries Limited (SUNPHARMA)
- Divi's Laboratories Limited (DIVISLAB)
- Torrent Pharmaceuticals Limited (TORNTPHARM)
- Laurus Labs Limited (LAURUSLABS)
- Zydus Lifesciences Limited (ZYDUSLIFE)
- Dr. Reddy's Laboratories Limited (DRREDDY)
- Cipla Limited (CIPLA)
- Mankind Pharma Limited (MANKIND)
- Aurobindo Pharma Limited (AUROPHARMA)
- Lupin Limited (LUPIN)
- Max Healthcare Institute Limited (MAXHEALTH)
- Glenmark Pharmaceuticals Limited (GLENMARK)
Source: consolidated SEBI Integrated Filing for the quarter ended 30 Jun 2026 and NSE daily closes. Open the interactive terminal view for charts and the full statements.
TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing. Figures are as filed with NSE/SEBI and as of the dates shown; they are not live prices.